Cannabis Rescheduling Hearing Delayed Until June 2026
Federal marijuana rescheduling faces major setback with hearing pushed back nearly two years, creating uncertainty for cannabis operators and investors.
The Drug Enforcement Administration has scheduled a formal hearing on marijuana rescheduling for June 29, 2026, marking a substantial delay in the federal review process that began under the Biden administration. The extended timeline pushes any potential rescheduling decision well beyond the current administration and into the next presidential term, creating prolonged regulatory uncertainty for cannabis operators.
The delay represents a significant setback for multi-state operators who have been banking on federal rescheduling to unlock banking services and reduce the punitive 280E tax burden that limits business deductions. Companies like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) have structured expansion plans around anticipated federal reform, with some operators carrying substantial debt loads in expectation of improved access to traditional financing.
Cannabis stocks have traded sideways for months as investors await clarity on federal policy direction. The rescheduling process, which would move marijuana from Schedule I to Schedule III under the Controlled Substances Act, has faced mounting opposition from law enforcement groups and some medical associations. The extended hearing timeline suggests the DEA anticipates substantial public testimony and regulatory review before making a final determination.
The delay also complicates state-level expansion strategies for major operators. Many companies have paused aggressive growth plans pending federal clarity, as rescheduling would fundamentally alter the competitive landscape by potentially allowing interstate commerce and reducing regulatory compliance costs. Without near-term federal action, operators must continue navigating the complex patchwork of state regulations while competing against illicit markets.
Investors now face nearly two more years of regulatory limbo, during which cannabis companies must demonstrate profitability under current constraints. The extended timeline favors well-capitalized operators with strong state-level market positions while potentially forcing smaller players to seek consolidation opportunities or exit the market entirely.